

Inflammation

Latest Filgotinib Updates

Jyseleca received regulatory approvals in Europe and Japan; launched in Germany

Pausing enrollment of trials in psoriatic arthritis, ankylosing spondylitis and uveitis

Phase 2b/3 SELECTION UC trial results presented at UEGW

Planning to file filgotinib for UC in Europe by YE

Upcoming Type A FDA meeting expected to inform broader development program

Expect to provide updates in coming months

We remain committed to inflammation and to our long-term collaboration with Galapagos



Inflammatory Disease Pipeline

			Pre-Clinical	Phase 1	Phase 2	Phase 3	NDA/MAA	Updates since Q2'20
Inflammatory Disease	Jyseleca filgotinib ¹	Rheumatoid arthritis	▲	MAA Approval				MAA Approval
	Filgotinib JAK-1 inhibitor (GS-6034)	Ulcerative colitis						
	Filgotinib JAK-1 inhibitor (GS-6034)	Crohn's Disease						
	Filgotinib JAK-1 inhibitor (GS-6034)	Psoriatic arthritis	▲					Trial Paused
	Filgotinib JAK-1 inhibitor (GS-6034)	Ankylosing spondylitis	▲					Trial Paused
	Filgotinib JAK-1 inhibitor (GS-6034)	Uveitis	▲					Trial Paused
	TPL2 inhibitor (GS-4875)	Ulcerative colitis						
	IRAK4 inhibitor (GS-5718)	Inflammatory Bowel Disease						
	α4β7 inhibitor (GS-1427)	Inflammatory Bowel Disease						
	Small molecule inhibitor (neutrophil target)	Inflammatory Diseases						
Small molecule inhibitor (innate immunity target)	Inflammatory Diseases							
Fibrotic Disease	Cilofexor FXR agonist (GS-9674)	PSC						
	Ziritaxestat ATX inhibitor (GLPG-1690)	IPF						
	Cilofexor / firsocostat combination ²	NASH						
	Selonsertib ASK1 inhibitor (GS-4997)	DKD						
	Ziritaxestat ATX inhibitor (GLPG-1690)	Systemic Sclerosis						
Options	Galapagos	Inflammatory and Fibrosis Diseases		7 clinical stage programs				
	Galapagos	Inflammatory and Fibrosis Diseases		6 pre-clinical stage programs				

★ New listing since Q2'20 ▲ Change since Q2'20
● Breakthrough Therapy Designation

¹ Received Japan approval and FDA Complete Response Letter. ² Combination of cilofexor (FXR agonist) and firsocostat (ACC inhibitor). Selected pre-clinical assets displayed. DKD – Diabetic kidney disease. IPF – Idiopathic pulmonary fibrosis. NASH – Nonalcoholic steatohepatitis. PSC – Primary sclerosing cholangitis. Pipeline shown above as of Q3'20.

